Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
De-Sheng WangZhi-Qiang WangGong ChenJie-Wen PengWei WangYan-Hong DengFeng-Hua WangJian-Wei ZhangHan-Lin LiangFen FengChuan-Bo XieChao RenYing JinSi-Mei ShiWen-Hua FanZhen-Hai LuPei-Rong DingFeng WangRui-Hua XuYu-Hong LiPublished in: Cancer medicine (2019)
Patients receiving GM1 were less troubled by the symptoms of acute neuropathy. However, we do not support the use of GM1 to prevent cumulative neurotoxicity. (ClinicalTrials.gov number, NCT02251977).
Keyphrases
- placebo controlled
- phase iii
- double blind
- clinical trial
- phase ii
- open label
- phase ii study
- study protocol
- drug induced
- high glucose
- liver failure
- diabetic rats
- physical activity
- squamous cell carcinoma
- aortic dissection
- sleep quality
- respiratory failure
- randomized controlled trial
- hepatitis b virus
- depressive symptoms
- radiation therapy
- oxidative stress